These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20627557)

  • 21. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
    Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
    Kim KH; Wissner A; Floyd MB; Fraser HL; Wang YD; Dushin RG; Hu Y; Olland A; Guo B; Arndt K
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5225-8. PubMed ID: 19628388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based optimization of potent PDK1 inhibitors.
    Angiolini M; Banfi P; Casale E; Casuscelli F; Fiorelli C; Saccardo MB; Silvagni M; Zuccotto F
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4095-9. PubMed ID: 20621725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.
    Saleem RS; Lansdell TA; Tepe JJ
    Bioorg Med Chem; 2012 Feb; 20(4):1475-81. PubMed ID: 22285028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of substituted 3-anilino-quinolin-2(1H)-ones as PDK1 inhibitors.
    O'Brien NJ; Brzozowski M; Wilson DJ; Deady LW; Abbott BM
    Bioorg Med Chem; 2014 Jul; 22(14):3781-90. PubMed ID: 24856302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AGC kinases, mechanisms of regulation ‎and innovative drug development.
    Leroux AE; Schulze JO; Biondi RM
    Semin Cancer Biol; 2018 Feb; 48():1-17. PubMed ID: 28591657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
    AbdulHameed MD; Hamza A; Liu J; Zhan CG
    J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
    Abraham S; Hadd MJ; Tran L; Vickers T; Sindac J; Milanov ZV; Holladay MW; Bhagwat SS; Hua H; Ford Pulido JM; Cramer MD; Gitnick D; James J; Dao A; Belli B; Armstrong RC; Treiber DK; Liu G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5296-300. PubMed ID: 21802948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA.
    Biondi RM; Cheung PC; Casamayor A; Deak M; Currie RA; Alessi DR
    EMBO J; 2000 Mar; 19(5):979-88. PubMed ID: 10698939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
    Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
    Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Ustilago maydis Aurora kinase as a novel antifungal target.
    Tückmantel S; Greul JN; Janning P; Brockmeyer A; Grütter C; Simard JR; Gutbrod O; Beck ME; Tietjen K; Rauh D; Schreier PH
    ACS Chem Biol; 2011 Sep; 6(9):926-33. PubMed ID: 21671622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound.
    Zhang H; Neimanis S; Lopez-Garcia LA; Arencibia JM; Amon S; Stroba A; Zeuzem S; Proschak E; Stark H; Bauer AF; Busschots K; Jørgensen TJ; Engel M; Schulze JO; Biondi RM
    Chem Biol; 2014 Jun; 21(6):754-65. PubMed ID: 24836908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.
    Medina JR
    J Med Chem; 2013 Apr; 56(7):2726-37. PubMed ID: 23448267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aza-stilbenes as potent and selective c-RAF inhibitors.
    McDonald O; Lackey K; Davis-Ward R; Wood E; Samano V; Maloney P; Deanda F; Hunter R
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5378-83. PubMed ID: 16890436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.